In this respect, results of our current study lent not only support to the previous CRP and Alb blend investigations in GBM patients, yet they additionally proposed a solid and independent role for the novel serum-based systemic inflammation marker CRP/Alb in prognostic stratification of newly diagnosed GBM patients undergoing to the standard RT plus TMZ combination therapy. Here, CRP is linked to glioblastoma.